The Conservative View on the Current Peptide Craze
A peptide is a short protein. There are countless such molecules present in the body. If used as a basis for therapy, a peptide is generally injected rather than taken orally as only a very small range of peptides can survive the digestive tract. Indeed, only a very small number of proteins more generally can survive outside of their specialized location inside a cell. So when people talk about peptides for therapy, they are talking about a tiny fraction of the peptides present in the body, largely those that are in some way involved in signaling between cells and thus can be found circulating through blood and tissues. Of that still very large number of peptides, a handful have been developed or are under development as potential therapies.
In recent years the same sort of people who enthusiastically sell dietary supplements on the basis of minimal data, cherry-picked studies, and a lot of hype and marketing have now discovered the existence of injectable peptides. There is something of a craze developing for a handful of known peptides that include a few approved for use with specific conditions outside the US, a few that have some animal studies and no human data whatsoever, and others in between those extremes. That GLP-1 receptor agonists are peptides has only fueled this hype cycle.
The US regulatory system for medicine has some quirks. One of those quirks is the existence of compounding pharmacies, regulated by states rather than the federal government. Very roughly, there is a whitelist of compounds that a compounding pharmacy is allowed to sell to patients, and that whitelist is largely determined by whether anyone has published a rigorous manufacturing protocol, regardless of whether or not the compound was approved for use in patients by the FDA. A lot of peptides being sold by the enthusiasts fall into this category. Further, the supplement industry is also in its own regulatory category, distinct from any sort of FDA drug approval, and also largely focused on manufacturing and quality control. Supplement industry lobbyists are apparently trying to have peptides included into their remit as well (a tough sell for injectable compounds to be called dietary supplements, but people do like to follow the money; a lot of self-interest at work there).
Needless to say, there are those on the more scientific and pro-regulation side of the house who are horrified by this sudden expansion of what they see as a blight upon the way things should be run. If they haven't been as vocal about the supplement industry in recent years, it is because they have been worn down by its excesses over the decades. Generally these commenters are in favor of the federal regulatory status quo for drugs to be more broadly applied. I think that the sane position is to be strongly against the present regulatory status quo, as it is clearly harmful to the pace of technological progress in medicine, while also recognizing that (a) it isn't great that some people are taking unnecessary and often ill-advised risks in the matter of peptides, and (b) education is an ethically better approach than regulation by force. People will sometimes do stupid things; freedom comes with responsibility. Trying to take away freedom of choice has side-effects that cause more harm over the long term, as we can see from the way in which the enormous and largely unnecessary costs imposed on medical development have impeded progress towards longer, healthier lives.
The recent expansion of peptide-based medicines has been especially visible in metabolic disease. GLP-1 receptor agonists and related incretin-based therapies have reshaped the treatment of type 2 diabetes and obesity, with agents such as semaglutide and tirzepatide demonstrating substantial effects on body weight and cardiometabolic outcomes in clinical trials. However, the visibility of approved peptide therapies has coincided with rising nonclinical peptide experimentation. The public success of GLP-1 receptor agonists has made injectable metabolic therapies more visible and normalized in public discourse, particularly for goals related to weight, metabolism, and body composition.
This legitimacy appears to be spilling over into a less regulated consumer marketplace, where experimental, investigational, or weakly evidenced peptides are promoted for fat loss, injury recovery, longevity, cognition, libido, aesthetics, sleep, muscle gain, and performance enhancement. The concern is not that all peptides are equivalent, but that digital discourse and online access pathways may blur distinctions between approved medicines, compounded products, investigational drugs, research chemicals, context-specific clinical therapies, preclinical compounds, and products supported mainly by anecdote or marketing.
This blurring is amplified by biohacking culture, longevity medicine, wellness clinics, and influencer-led health optimization. Biohacking and do-it-yourself biology communities have been shaped partly through online forums and digital spaces where users exchange knowledge, techniques, protocols, and interpretations of biological self-experimentation. In peptide-related discussions, compounds are frequently framed as tools for optimization, recovery, performance, aesthetics, cognition, or longevity, with terms such as "stacks," "protocols," "research peptides," "tier lists," and "longevity peptides" creating a shared language of self-experimentation. These digital sources should not be interpreted as evidence of clinical efficacy or safety. However, they are relevant to public health because online creators, forums, and wellness communities can influence how health products are perceived, normalized, sourced, combined, and interpreted outside formal clinical supervision.
Gray-market access is central to this exposure pathway. Many peptide products are sold online with disclaimers such as "for research use only" or "not for human consumption," while being discussed in consumer spaces as substances for personal use. Certificates of analysis, purity claims, and biomedical language may provide reassurance, even when products have not undergone the regulatory review, manufacturing oversight, or postmarketing surveillance expected for approved medicines. In this gray-market environment, access may appear medically adjacent while remaining weakly accountable, poorly traceable, and difficult to monitor through conventional pharmacovigilance systems.